JCM
HAE icon

JS Capital Management’s Haemonetics HAE Stock Holding History

JS Capital Management’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,100
Closed -$278K – 181
2020
Q2 		$278K Buy
+3,100
New +$313K 0.02% 124
2020
Q1 		– Sell
-2,100
Closed -$241K – 152
2019
Q4 		$241K Buy
+2,100
New +$254K 0.03% 106

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JS Capital Management's HAE Position: Q3 2020 in Review

JS Capital Management sold out of Haemonetics (HAE) in Q3 2020, closing a stake of 3,100 shares — an estimated $278K sold.

JS Capital Management first reported a position in HAE in Q4 2019 and held it in 2 quarters. The position peaked at $278K in Q2 2020. 268 funds tracked by Wall St. Rank hold HAE as of Q3 2020.

  • JS Capital Management reported no remaining Haemonetics position as of Q3 2020 after selling out during the quarter.
  • JS Capital Management sold 3,100 Haemonetics shares in Q3 2020, an estimated $278K.
  • JS Capital Management first reported a position in Haemonetics in Q4 2019 and held it in 2 quarters.
  • JS Capital Management's Haemonetics position peaked at $278K in Q2 2020.
  • 268 funds tracked by Wall St. Rank held Haemonetics as of Q3 2020.

Based on JS Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.